Fig. 7

Wound surface area reduction in DFU patients treated with ABCB5⁺ MSCs. A–B Percent wound surface area reduction from baseline during the treatment and efficacy follow-up period in the full analysis set (A) and per-protocol set (B). Patients who presented with wound surface area reductions of at least 30% from baseline (indicated by light green dashed lines) at week 12 were considered responders. Error bars indicate median and interquartile range; p values (two-sided Wilcoxon signed rank test) indicate statistical significance of changes from baseline. C Tukey’s boxplots of the primary efficacy outcome parameter, % wound surface area reduction from baseline at week 12, in the full analysis set (FAS, N = 23), per-protocol set (PP, N = 20) and responders (i.e., patients who presented with at least 30% wound surface area at week 12; N = 17). D-E Kaplan–Meier plots for the time to full wound closure (D) and first 30% surface area reduction (E) in the FAS, PP and responders. Patients without event were censored at the date of the last available wound surface area assessment (indicated by small vertical ticks). Vertical dashed lines indicate median time to event (not reached for full wound closure)